Oral JAK/SYK-inhibition (ASN002) suppresses inflammation and improves epidermal barrier markers in atopic dermatitis.

Ana B Pavel,Teresa Song,Hyun-Je Kim,Ester Del Duca,James G Krueger,Celina Dubin,Xiangyu Peng,Hui Xu,Ning Zhang,Yeriel D Estrada,Louis Denis,Niranjan Rao,Sandeep Gupta,David J Zammit,Robert Bissonnette,Emma Guttman-Yassky

Journal of Allergy and Clinical Immunology（2019）

引用 84|浏览34

暂无评分

摘要

The JAK/SYK inhibitor ASN002 significantly suppressed key AD inflammatory pathways, corresponding to clinical response. ASN002 may be an effective novel therapeutic agent for moderate-to-severe AD.

查看译文

关键词

Atopic dermatitis,ASN002,Janus kinase,spleen tyrosine kinase,Janus kinase inhibitors,spleen tyrosine kinase inhibitors,tyrosine kinase,TH2,TH22,TH17,barrier

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要